XNASPROK
Market cap484mUSD
Jan 08, Last price
1.66USD
1D
-9.29%
1Q
-2.35%
IPO
-80.76%
Name
ProKidney Corp
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-35m
L-76.06%
CFO
-90m
L+16.84%
Earnings
Mar 20, 2025
Profile
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | |||||
Cost of revenue | 154,691 | 156,043 | |||
Unusual Expense (Income) | |||||
NOPBT | (154,691) | (156,043) | |||
NOPBT Margin | |||||
Operating Taxes | 5,996 | 896 | |||
Tax Rate | |||||
NOPAT | (160,687) | (156,939) | |||
Net income | (35,468) -76.06% | (148,135) 168.62% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | (9,499) | 6,050 | |||
BB yield | 8.65% | -1.43% | |||
| Debt | |||||
Debt current | 803 | 493 | |||
Long-term debt | 7,220 | 4,305 | |||
Deferred revenue | |||||
Other long-term liabilities | 568 | 278 | |||
Net debt | (354,927) | (485,454) | |||
| Cash flow | |||||
Cash from operating activities | (90,069) | (77,089) | |||
CAPEX | (34,197) | (1,846) | |||
Cash from investing activities | (329,983) | (1,738) | |||
Cash from financing activities | (9,551) | 548,521 | |||
FCF | (194,029) | (157,404) | |||
| Balance | |||||
Cash | 362,950 | 490,252 | |||
Long term investments | |||||
Excess cash | 362,950 | 490,252 | |||
Stockholders' equity | 355,222 | 497,463 | |||
Invested Capital | 41,095 | 17,086 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 61,714 | 61,540 | |||
Price | 1.78 -74.05% | 6.86 | |||
Market cap | 109,851 -73.98% | 422,166 | |||
EV | 1,249,656 | 1,538,267 | |||
EBITDA | (150,838) | (153,007) | |||
EV/EBITDA | |||||
Interest | 12 | 215 | |||
Interest/NOPBT | |||||